Nevro Corp. NVRO recently announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT) in Diabetes Research and Clinical Practice. The ...
Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep Published 24-month data from the ...
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...
Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts ...
Nevro got a CE mark for a new version of its spinal cord stimulation (SCS) therapy for chronic pain. Nevro’s Senza II SCS system is smaller than its original Senza device but provides the same HF10 ...
On February 7, 2025, Nevro Corp was acquired by Globus Medical (NYSE:GMED) in an all-cash transaction valuing NVRO at $5.85 per share, representing a total equity value of approximately $250 million.
Nevro Corp. NVRO recently announced that it has received CE mark approval for the Senza Omnia Spinal Cord Stimulation (SCS) system. This is a next-generation SCS system, which has been created and ...
Nevro Corp. NVRO recently announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results